Validation of Combined PET-MR Quantitative Parameters for Cardiac Applications
Trial Snapshot
- Phase
- Not Applicable
- Status
- Terminated
- Enrollment
- 2
- Locations
- 1
- Primary Endpoint
- Number of Quality PET and PET/MR Images With Regional Myocardial Uptake of 18F-Fluorodeoxyglucose (FDG) in Participants Without Overt Diagnosis of Ischemic Coronary Artery Disease.
Study Overview
Brief Summary
The purpose of this study is to understand how simultaneous PET/MR acquisition can provide novel qualitative and quantitative biomarkers to guide clinical intervention and predict prognosis of patients with cardiovascular disease.
Detailed Description
- To compare regional myocardial uptake of FDG on images obtained on a standard PET camera with the new PET/MR camera, in patients with coronary artery disease.
- To compare viability maps obtained with cardiac MR images and FDG-PET for delineation of myocardial infarct core and border zone, in patients with coronary artery disease.
- To correlate MRI myocardial strain with relative myocardial FDG uptake in patients with a previous myocardial infarction.
- To interrogate if simultaneous acquisition of cardiac PET and viability cardiac MR differ from acquisitions obtained independently, with special focus on attenuation correction methods
- To combined MRI scar map with FDG-PET uptake in patients with cardiac sarcoidosis and myocarditis.
- To correlate morphologic characteristics of atherosclerotic disease in the thoracic and abdominal aorta with FDG uptake and ferumoxytol enhancement, as a marker of inflammation.
- To evaluate cardiac strain and myocardial scar burden in obese patients with and without diabetes.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Diagnostic
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to 90 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Subjects with ischemic and non-ischemic cardiac disease referred for cardiac PET for viability imaging.
Exclusion Criteria
- •Contraindications for MRI, including cardiac pacemaker, claustrophobia, retained metallic foreign body, cochlear implant, Aneurysm clip in the brain, pregnancy and eGFR less than 45%.
Arms & Interventions
Cardiac patients receiving PET/MR
PET-MRI with intravenous Gadolinium and FDG. The entire study will take approximately one hour.
Intervention: PET-MRI (Device)
Outcomes
Primary Outcomes
Number of Quality PET and PET/MR Images With Regional Myocardial Uptake of 18F-Fluorodeoxyglucose (FDG) in Participants Without Overt Diagnosis of Ischemic Coronary Artery Disease.
Time Frame: 2 hours
Visual analysis of collected image pairs. Evaluated by experienced imaging providers as yes or no.
Secondary Outcomes
No secondary outcomes reported
